VLX-1005 is under clinical development by Veralox Therapeutics and currently in Phase II for Heparin-Induced Thrombocytopenia. According to GlobalData, Phase II drugs for Heparin-Induced Thrombocytopenia have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VLX-1005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VLX-1005 is under development for the treatment of heparin-induced thrombocytopenia (HIT), and HIT with thrombosis (HITT) and Type 1 diabetes. The therapeutic candidate acts by targeting 12 lipoxygenase (12-LOX) enzyme. It is administered through intravenous route and oral route.
Veralox Therapeutics overview
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company is headquartered in Frederick, Maryland, the US
For a complete picture of VLX-1005’s drug-specific PTSR and LoA scores, buy the report here.